Alzheimer’s drug Leqembi could be given as shots rather than IV infusion, study suggests

Leqembi's New Administration Method: The Alzheimer’s drug Leqembi, the first to slow the disease's progression, may soon transition from bi-weekly intravenous infusions to two weekly shots administered at home, as suggested by a study from drugmaker Eisai. This alternative method aims to provide a more convenient treatment process for patients.

Study Findings and FDA Approval: Research presented at the Clinical Trials on Alzheimer’s Disease conference in Boston indicated that the shot version, given subcutaneously, produced results similar to the IV method over a span of six months. These results encompassed safety metrics, drug concentration in the bloodstream, and the ability to clear amyloid plaques in the brain.

Future Prospects and Considerations: Eisai is gearing up to file an application for FDA approval of the weekly shot form by the end of March next year. The shots could be self-administered or given by a caregiver. However, it's crucial for prescribers to ensure patients are well-informed on its use and can consistently administer it, alongside appropriate safety monitoring.